Sponsored by
Researchers at the University of Pennsylvania have found that a 70-year-old blood pressure drug, hydralazine, blocks an oxygen-sensing enzyme called ADO—a molecular “alarm” that controls blood vessel constriction. This discovery is relevant for brain cancer, because glioblastoma relies on the ADO pathway to survive in low-oxygen environments. When researchers tested hydralazine on glioblastoma cells in the lab, it pushed them into a non-dividing, dormant state known as senescence. While this finding is exciting, hydralazine has poor blood-brain barrier penetrance, so the next step will likely be development of new ADO inhibitors that are more tissue specific and better at crossing the blood-brain barrier.